Abcam, ab259225, Human UBE2O knockout HeLa cell lysate

Size: 1Kit
UBE2O KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 8 and 2 bp deletion in exon 8.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 8 and 2 bp deletion in exon 8.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-UBE2O, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
UBE2O also known as E2-230K or E2 ubiquitin-conjugating enzyme O is a protein that functions as an E2 ubiquitin-conjugating enzyme. It has a molecular mass of approximately 141 kDa. UBE2O plays a role in transferring ubiquitin to substrate proteins marking them for degradation via the proteasome. This process is important for protein quality control and cellular homeostasis. UBE2O is expressed in various tissues including the brain liver and skeletal muscle indicating its broad physiological significance.
Biological function summary
UBE2O facilitates the regulation of protein turnover by mediating ubiquitination without the need for an E3 ligase. It acts both as an E2 and has E3 activity making it a versatile factor in the ubiquitin-proteasome system. UBE2O also participates in muscle differentiation by targeting specific muscle regulatory factors for ubiquitination. Understanding its function provides insights into the control of muscle mass and function highlighting its contribution to cellular growth and adaptation.
Pathways
UBE2O interacts with essential biological mechanisms notably the ubiquitin-proteasome pathway involved in protein degradation. It also participates in cell cycle regulation by targeting certain cyclin proteins for degradation ensuring proper cell cycle progression. UBE2O works in conjunction with other proteins like ANAPC10 and CDC20 which are important in cell cycle control and proteostasis.
UBE2O has associations with conditions such as myopathies and certain cancers. In muscle disorders UBE2O dysregulation can lead to abnormal protein accumulation affecting muscle function. In oncology UBE2O interacts with proteins like P53 which is important in cell cycle regulation and apoptosis. Its role in these disorders underlines its importance as a potential therapeutic target for intervention in these diseases.